GlassScriptPhysician profile
Jordan Mussary
NPI 1962484477
$1,890.35
in general payments reported to CMS, 2019-2025
23 companies · $379 in 2025
The $379 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $128 · 2021: $293 · 2022: $263 · 2023: $98.99 · 2024: $495 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $313.72 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $245.13 | 2019-2024 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $195.29 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $141.32 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $135.74 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $118.13 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Corium, LLC | $102.63 | 2021-2024 | Azstarys |
| Adlon Therapeutics L.P. | $68.08 | 2019-2021 | |
| Pfizer INC. | $68.04 | 2019-2022 | |
| Alk-Abello, INC | $67.87 | 2025 | Neffy, Odactra, Grastek |
| Sanofi-Aventis U.S. LLC | $59.27 | 2024 | |
| Neos Therapeutics, LP | $57.07 | 2019 | |
| Sanofi Pasteur INC. | $53.28 | 2019-2021 | |
| Smith+Nephew, INC. | $40.74 | 2022 | |
| Verrica Pharmaceuticals INC. | $37.98 | 2024 | Ycanth |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $37.49 | 2021-2025 | Bexsero |
| Cranial Technologies, INC | $28.50 | 2022-2023 | Doc Band |
| Ultragenyx Pharmaceutical INC. | $26.27 | 2023 | Crysvita |
| Phadia US INC. | $23.68 | 2024 | Immunocap |
| Organon LLC | $20.78 | 2025 | |
| Abbvie INC. | $18.94 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.91 | 2025 | Zoryve |
| Vertical Pharmaceuticals, LLC | $13.49 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Mussary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.